Extensions of 'worst-rank' score methods with outcomes truncated by death
|
|
13
|
3036
|
September 2, 2021
|
Resources for Mixed-Effect Models in Medical Contexts
|
|
7
|
3185
|
August 8, 2021
|
Heterogeneity in RCTs with continuous outcome
|
|
19
|
9071
|
July 2, 2021
|
Default Using R package to implement Bayesian phase I/II dose-finding design for three outcomes
|
|
10
|
3650
|
June 10, 2021
|
Multiplicity in clinical trials with hierarchical strategy
|
|
2
|
5350
|
December 30, 2020
|
RCT trials for COVID study vaccines
|
|
0
|
3126
|
October 24, 2020
|
Can treatment B be superior after the RCT if it was thought that treatment A is superior before the RCT?
|
|
5
|
3139
|
October 13, 2020
|
"Open label, double-masked trial"
|
|
0
|
3435
|
October 13, 2020
|
ANCOVA with randomized and nonrandomized groups
|
|
4
|
3208
|
September 30, 2020
|
Time since randomization and causality
|
|
2
|
2352
|
September 27, 2020
|
Bayesian Solutions for Challenges to Frequentist Statistics
|
|
0
|
5493
|
September 22, 2020
|
Empirical Bayes for RCT Interpretarion
|
|
8
|
5392
|
August 11, 2020
|
Re-starting a Bayesian group sequential design trial after stopping it
|
|
4
|
2948
|
August 11, 2020
|
MERINO trial - adjusting for infection source
|
|
3
|
5316
|
August 3, 2020
|
Thoughts on 'representativeness' and 'generalizability'
|
|
6
|
4086
|
July 19, 2020
|
Interpretation of INTERACT-2 Study in Intracerebral Hemorrhage
|
|
3
|
4811
|
June 15, 2020
|
Open-label RCT of triple combination (LPV/r, Ribavirin, Interferon) on SARS-CoV2
|
|
1
|
3149
|
May 15, 2020
|
Type I error in a specific design of 2-parallel group study
|
|
3
|
3669
|
March 11, 2020
|
RCT generalizability and interactions with treatment
|
|
8
|
4756
|
March 10, 2020
|
Presenting models of multiple (potentially recurring) outcomes
|
|
1
|
3548
|
March 6, 2020
|
Power for interaction effects
|
|
6
|
5004
|
February 24, 2020
|
Open label RCT: Placebo or Real effect?
|
|
5
|
5198
|
February 5, 2020
|
Handling withdrawn study subjects
|
|
6
|
5092
|
February 4, 2020
|
Marginal vs conditional (Mixed) models used in Joint model analysis. The SPRINT trial controversy
|
|
9
|
7183
|
December 2, 2019
|
2019 Nobel Prize in Economic Sciences is about limitations of RCT
|
|
15
|
5962
|
November 5, 2019
|
Adherence adjustment in randomized trials is possible, here's why
|
|
4
|
5674
|
July 9, 2019
|
RCT ceiling effects and high drop off rate
|
|
6
|
6286
|
October 14, 2019
|
How much patient variability is best for a clinical trial?
|
|
5
|
3947
|
September 22, 2019
|
Deviation in primary endpoint definition
|
|
12
|
6916
|
July 26, 2019
|
Advice/Opinion on (reviewing - ethics) an RCT analysis plan
|
|
1
|
2207
|
June 28, 2019
|